Neoadjuvant and adjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast cancer

Clinical Breast Cancer

Volumn 5, Issue 5, 2004, Pages 377-384

  Malhotra, Vikas ^a   Dorr, Victoria J ^a   Lyss, Alan P ^b   Anderson, Clay M ^a   Westgate, Steven ^a   Reynolds, Michelle ^a   Barrett, Barbara ^a   Perry, Michael C ^a  

^a UNIVERSITY OF MISSOURI   (United States)

^b MISSOURI BAPTIST MEDICAL CENTER   (United States)

Author keywords

Anthracycline; Pathologic response; Preoperative chemotherapy; Radiation therapy; Surgery; Taxane

Indexed keywords

DOCETAXEL; DOXORUBICIN; RAZOXANE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN;

ADULT; ADVANCED CANCER; AGED; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CAUSE OF DEATH; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG FATALITY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FLUID RETENTION; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART DEATH; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HISTOPATHOLOGY; HUMAN; MASTECTOMY; MINIMAL RESIDUAL DISEASE; MYALGIA; NAIL DISEASE; NEUTROPENIA; PARTIAL MASTECTOMY; PATIENT MONITORING; PERIPHERAL NEUROPATHY; SIDE EFFECT; SUDDEN DEATH; SYMPTOMATOLOGY; TREATMENT INDICATION; TUMOR VOLUME;

EID: 12144262655     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2004.n.045     Document Type: Article

References (46)

1. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16:2672-2685.
2. Scholl SM, Pierga JY, Asselain B, et al. Breast tumor response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 1995; 31A:1969-1975.
3. Mamounas EP, Fisher B. Preoperative chemotherapy in patients with breast cancer. Semin Oncol 2001; 28:389-399.
4. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003; 21:4165-4174.
5. Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998; 351:1451-1467.
6. Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339:1-15.
7. Early Breast Cancer Trialists Collaborative Group. Poly chemotherapy for early breast cancer: An overview of the randomized trials. Lancet 1998; 352:930-942.
8. Ravdin PM, Burris HA, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995; 13:2879-2886.
9. Clemons M, Leahy M, Valle J, et al. Review of recent trials of chemotherapy for advanced breast cancer: the taxanes. Eur J Cancer 1997; 33:2183-2193.
10. Piceart MJ, Awada A, Hamilton A. Integration of new therapies into management of metastatic breast cancer: a focus on chemotherapy, treatment selection through use of molecular markers, and newly developed biologic therapies in late clinical development. In: Perry, MC, ed. American Society of Clinical Oncology Educational Book. Alexandria, VA: American Society of Clinical Oncology; 1999:526-539.
11. Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995; 13:2886-2894.
12. Nabholtz JM, Crown J. Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results. Semin Oncol 1998; 25:4-9.
13. Ten Bokkel Huinink WN, Paridaens R, Piccart M, et al. Docetaxel (DOC) in heavily pretreated metastatic breast cancer (MBC): analysis of an international compassionate-use trial. Proc Am Soc Clin Oncol 1999; 18:120a (Abstract #455).
14. Von Minckwitz G, Costa SD, Raab G, et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study. J Clin Oncol 2001; 19:3506-3515.
15. Marcus E, Shiomoto G, Holden C, et al. The efficacy of doxorubicin and docetaxel (Taxotere) in a phase II trial of neoadjuvant treatment of locally advanced breast cancer. Breast Cancer Res Treat 1999; 57:69 (Abstract #254).
16. Smith IC, Heys S, Hutcheon A, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002; 20:1456-1466.
17. American Cancer Society. Cancer Facts & Figures 2004. Atlanta, GA; ACS: 2004.
18. Beahrs OH, Myers MH, eds. Manual for staging of cancer. 2nd ed. Philadelphia: JB Lippincott, 1983:127-135.
19. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, eds: Handbook for Staging of Cancer. 4th ed. Philadelphia, PA: JB Lippincott; 1993:161-167.
20. Hortobagyi GN, Singletary SE, Strom EA. Treatment of locally advanced breast cancer. In: Harris JR, Lippman ME, Morrow M, et al, eds. Diseases of the breast. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2000:645-650.
21. Duggan D. Local Therapy of Locally Advanced Breast Cancer. Oncology 1991; 12:67-74.
22. Sheldon T, Hayes DF, Cady B, et al. Primary radiation therapy for locally advanced breast cancer. Cancer 1987; 60:1219-1225.
23. Montague ED, Fletcher GH. Local regional effectiveness of surgery and radiation therapy in the treatment of breast cancer. Cancer 1985; 55:2266-2272.
24. Bedwinek J, Rao D, Perez C, et al. Stage III and localized stage IV breast cancer: Irradiation alone versus irradiation plus surgery. Int J Radiat Oncol Biol Phys 1982; 8:31-36.
25. Klefstrom P, Grohn P, Heinonen E, et al. Adjuvant postoperative radiotherapy, chemotherapy, and immunotherapy in stage III breast cancer. II. 5-year results and influence of levamisole. Cancer 1987; 60:936-942.
26. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16:2672-2685.
27. Ferriere JP, Assier I, Cure H, et al. Primary chemotherapy in breast cancer: correlation between tumor response and patient outcome. Am J Clin Oncol 1998; 21:117-120.
28. Machiavelli MR, Romero AO, Pérez JE, et al. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 1998; 4:125-131.
29. Powles TJ, Hickish TF, Makris A, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 1995; 13:547-552.
30. Olson JE, Neuberg D, Pandya K, et al. The management of resectable stage III breast cancer. The Eastern Cooperative Oncology Group Trial. Proc Am Soc Clin Oncol 1989; 8:23 (Abstract #85).
31. Von Minckwitz G, Raab G, Schuette M, et al. Dose-dense versus sequential adriamycin/docetaxel combination as preoperative chemotherapy (pCHT) in operable breast cancer (T2-3, N0-2, M0)-primary endpoint analysis of the GEPARDUO-Study. Proc Am Soc Clin Oncol 2002; 21:43a (Abstract #168).
32. Hortobagyi GN, Ames FC, Buzdar AU, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 1988; 62:2507-2516.
33. Swain SM, Sorace RA, Bagley CS, et al. Neoadjuvant chemotherapy in the combined modality approach of locally advanced non-metastatic breast cancer. Cancer Res 1987; 47:3889-3894.
34. Israel L, Breau J, Morere J. Two years of high dose cyclophosphamide and 5-fluorouracil followed by surgery after 3 months for acute inflammatory breast carcinomas. Cancer 1986; 57:24-28.
35. Fischer B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15:2483-2493.
36. Morrow M, Braverman A, Thelmo W, et al. Multimodal therapy for locally advanced breast cancer. Arch Surg 1986; 121:1291-1296.
37. Feldman L, Hortobagyi G, Buzdar A, et al. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 1986; 46:2578-2581.
38. Broadwater J, Edwards M, Kuglen C. Mastectomy following preoperative chemotherapy. Ann Surg 1991; 213:126-129.
39. Bonadonna G, Valagussa P, Zambetti M, et al. Locally advanced breast cancer: 10 year results after combined treatment. Proc Am Soc Clin Oncol 1988; 7:9 (Abstract #33).
40. Perloff M, Lesnick GJ, Korzun A, et al. Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: A Cancer and Leukemia Group B Study. J Clin Oncol 1988; 6:261-269.
41. Perez CA, Graham ML, Taylor ME, et al. Management of locally advanced carcinoma of the breast. I. Noninflammatory. Cancer 1994; 74S:453-465.
42. Perez CA, Fields JN, Fracasso PM, et al. Management of locally advanced carcinoma of the breast. II: Inflammatory carcinoma. Cancer 1994;74S:466-476.
43. Delena M, Zucali R, Viganotti G, et al. Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol 1978; 1:53-59.
44. Newman L, Buzdar A, Singletary SE, et al. A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast conservation therapy feasibility. Ann Surg Oncol 2002; 9:228-234.
45. Nabholtz JM, Pienkowski T, Mackey J, et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 2002; 21:36a (Abstract #141).
46. Green MC, Buzdar AU, Smith T, et al. Weekly (wkly) paclitaxel (P) followed by FAC as primary systemic chemotherapy (PSC) of operable breast cancer improves pathologic complete remission (pCR) rates when compared to every 3-week (Q 3 wk) P therapy (tx) followed by FAC - final results of a prospective phase II randomized trial. Proc Am Soc Clin Oncol 2002; 21:35a (Abstract #135).